New hope for Hard-to-Treat colon cancer: first human trial launches

NCT ID NCT07321106

First seen Jan 07, 2026 · Last updated Apr 30, 2026 · Updated 17 times

Summary

This early-stage study tests a new drug, CBI-1214, for people with advanced colorectal cancer that hasn't responded to standard treatments. The drug aims to help the body's immune cells attack the cancer. About 80 participants will receive increasing doses to find the safest and most effective dose, while monitoring side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 91402, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.